Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.

Wang H, Larriviere KS, Keller KE, Ware KA, Burns TM, Conaway MA, Lacomis D, Pattee GL, Phillips LH 2nd, Solenski NJ, Zivkovic SA, Bennett JP Jr.

Amyotroph Lateral Scler. 2008 Feb;9(1):50-8. doi: 10.1080/17482960701791234.

PMID:
18270879
2.

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.

Gribkoff VK, Bozik ME.

CNS Neurosci Ther. 2008 Fall;14(3):215-26. doi: 10.1111/j.1755-5949.2008.00048.x. Review.

PMID:
18801114
3.

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.

Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M.

Neurology. 2005 Dec 13;65(11):1834-6.

PMID:
16344537
4.

Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.

Bennett J, Burns J, Welch P, Bothwell R.

J Alzheimers Dis. 2016;49(4):1179-87. doi: 10.3233/JAD-150788.

PMID:
26682692
5.
6.

Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment.

Pattee GL, Post GR, Gerber RE, Bennett JP Jr.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Jun;4(2):90-5.

PMID:
14506939
7.

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Jun;1(3):201-6.

PMID:
11464953
8.

Phase II/III randomized trial of TCH346 in patients with ALS.

Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, Strong M, Swash M, Vernotica E; TCH346 Study Group..

Neurology. 2007 Aug 21;69(8):776-84.

PMID:
17709710
9.

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, Clawson L, Haas L, Rothstein JD.

Amyotroph Lateral Scler. 2010 May 3;11(3):266-71. doi: 10.3109/17482960903307805.

PMID:
19961264
10.

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.

Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR; Northeast ALS Consortium..

Muscle Nerve. 2008 Jul;38(1):837-44. doi: 10.1002/mus.21059.

PMID:
18551622
11.
12.

Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.

Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, Antozzi C, Ciano C, Beretta P, Caldiroli D, Ghelma F, Ferrara G, Ghezzi P, Mantegazza R.

Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):410-5. doi: 10.3109/17482960902995246.

PMID:
19922132
13.

Xaliproden in amyotrophic lateral sclerosis: early clinical trials.

Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Jun;5(2):99-106.

PMID:
15204011
14.

Outcome measures for early phase clinical trials.

Gordon PH, Cheng B, Montes J, Doorish C, Albert SM, Mitsumoto H.

Amyotroph Lateral Scler. 2007 Oct;8(5):270-3.

PMID:
17852017
15.

Progression in ALS is not linear but is curvilinear.

Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, Lacomblez L, Meininger V.

J Neurol. 2010 Oct;257(10):1713-7. doi: 10.1007/s00415-010-5609-1. Epub 2010 Jun 8.

PMID:
20532545
16.

A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers.

Levine TD, Bowser R, Hank N, Saperstein D.

Amyotroph Lateral Scler. 2010 Dec;11(6):514-9. doi: 10.3109/17482968.2010.513052. Epub 2010 Sep 14.

PMID:
20839903
17.

Correlates of quality of life in ALS: Lessons from the minocycline study.

Lou JS, Moore D, Gordon PH, Miller R.

Amyotroph Lateral Scler. 2010;11(1-2):116-21. doi: 10.3109/17482960902918719.

PMID:
19551536
18.

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A.

J Neurol Sci. 1999 Oct 31;169(1-2):13-21.

PMID:
10540002
19.

High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies.

Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL.

Ann Neurol. 1994 Dec;36(6):920-4.

PMID:
7998781
20.

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.

Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):44-51. doi: 10.3109/17482968.2012.723723. Epub 2012 Sep 17.

PMID:
22985432

Supplemental Content

Support Center